688443 Chongqing Genrix Biopharmaceutical
- 22.30
- -0.65-2.83%
Chongqing Genrix Biopharmaceutical News
Announcement on the listing and circulation of part of the initial public offering of restricted shares
Inspection opinions of Haitong Securities Co., Ltd. on the initial public offering of Chongqing Zhixiang Jintai Biopharmaceutical Co., Ltd. and the listing circulation of some restricted shares
Announcement on holding the 2024 semi-annual results briefing
An indicative announcement on the chairman\'s proposal to repurchase the company\'s shares
Haitong Securities Co., Ltd.\'s 2024 continuous supervision semi-annual follow-up report on Chongqing Zhixiang Jintai Biopharmaceutical Co., Ltd.
Announcement of Resolutions of the 15th Meeting of the First Board of Directors
Special Report on the Deposit and Actual Use of Funds Raised for the Semiannual Year of 2024
Announcement of Resolutions of the 14th Meeting of the First Board of Supervisors
2024 Semi-Annual Report Summary
2024 Semi-Annual Report
Voluntary disclosure announcement on approval for marketing of celizumab as an indication for moderate to severe plaque psoriasis
Voluntary disclosure of the announcement on the approval of the drug clinical trial approval notice for the indication of GR1802 injection for children and adolescents with atopic dermatitis.
Voluntary disclosure regarding the commencement of Phase III clinical trials for GR2001 injection.
Voluntary disclosure announcement on the inclusion of GR1803 injection solution in the list of breakthrough therapeutic varieties.
Voluntary disclosure regarding the launch of Phase III clinical trial for GR1802 injection for the treatment of chronic sinusitis with nasal polyps.
Action plan for "Improving Quality, Increasing Efficiency, and Returning to Benefits" for the year 2024.
Announcement on the voluntary disclosure of GR2001 injection being included in the list of breakthrough therapeutic varieties.
Legal Opinion from Shanghai Jintiancheng Law Firm Regarding the 2023 Shareholders' Meeting of Chongqing Zhixiang Jintai Biopharmaceutical Co., Ltd.
Announcement of Resolutions of the Shareholders' Meeting for the Fiscal Year 2023
Announcement of reply to regulatory inquiry letter regarding information disclosure of 2023 annual report.
Analysis
Price Target
No Data
No Data